PDX Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- PDX Pharmaceuticals's estimated annual revenue is currently $1.9M per year.
- PDX Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- PDX Pharmaceuticals has 12 Employees.
- PDX Pharmaceuticals grew their employee count by -8% last year.
PDX Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Research & COO | Reveal Email/Phone |
2 | Research Associate | Reveal Email/Phone |
PDX Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2M | 13 | -55% | N/A | N/A |
#2 | $22.9M | 148 | 11% | N/A | N/A |
#3 | $7.4M | 48 | 9% | N/A | N/A |
#4 | $0.8M | 5 | 0% | N/A | N/A |
#5 | $39.9M | 206 | -2% | N/A | N/A |
#6 | $1.4M | 9 | -18% | N/A | N/A |
#7 | $2.8M | 18 | 6% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $9.1M | 59 | 13% | N/A | N/A |
#10 | $0.9M | 6 | 20% | N/A | N/A |
What Is PDX Pharmaceuticals?
PDX Pharmaceuticals is an IND-enabling stage biopharmaceutical company. We develop novel combination and immunotherapies to treat cancer by bringing complementary biological pathways together to achieve synergistic clinical benefit. Our therapeutic candidates bridge the innate and adaptive immune systems by generating profound CD8+ T cell production. Our pipelines are patented AIRISE (Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors) and ARAC (Antigen Release Agent and Checkpoint Inhibitor) pipelines that generate anti-tumor immunity when given locally (AIRISE) or systemically (ARAC) by relying on patient' s own tumor in situ as the source of antigens.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Portland
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 12 | 33% | $36.7M |
#2 | $1M | 12 | N/A | N/A |
#3 | $1M | 12 | N/A | N/A |
#4 | $1M | 12 | N/A | N/A |
#5 | $1M | 12 | 9% | N/A |